Atlas Trials

A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Clinical trial NCT07770074 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07770074
Sponsor
Novartis Pharmaceuticals
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Radioiodine-refractory Differentiated Thyroid Cancer
Start date
2026-10-08
Primary completion
2026-10-31
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.